Monograph
C09AA01 - Captopril |
Propably not porphyrinogenic |
PNP |
Rationale
Substrate of 2D6. In major parts not metabolised. No data pointing to CYP-induction or MI complex formation.
Risk for gastrointestinal adverse events in the form of nausea, vomiting, diarrhoea and obstipation motivates vigilance against insufficient intake of food, especially of carbohydrate.
Chemical description
ACE- inhibitor. 75% excreted in urine of which 50% is unchanged substance and the rest captoprilcystein and disulfide derivatives. Substrate of CYP 2D6. South African list: use with care. French list: authorized.
Therapeutic characteristics
Common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are nausea, vomiting, diarrhoea and obstipation.
IPNet drug reports
Uneventful use reported in 3 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Latvia
Serbia
